MaxCyte,
Inc.
("MaxCyte" or the "Company")
Total Voting
Rights
ROCKVILLE, MD, August 1,
2024: MaxCyte
Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering
focused company providing enabling platform technologies to advance
the discovery, development and commercialization of next-generation
cell therapeutics and to support innovative, cell-based
research, announces that pursuant to its block admission
facility, since June 30 it has issued 228,807 of common stock,
$0.01 par, of the Company ("Common Stock") in satisfaction of the
exercise of share options and/or vesting of restricted stock
units.
Total voting rights
As at 31 July 2024, the total issued
stock capital of the Company following the recent issue of the new
Common Stock is 105,052,931 shares of Common Stock. Shareholders in
the Company may use this figure as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
stock capital of the Company.
For further information, please
contact:
|
|
MaxCyte Contacts:
US IR
Adviser
Gilmartin Group
David Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
|
|
Nominated Adviser and Joint
Corporate Broker
Panmure Liberum
Emma Earl / Freddy
Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
|
|
UK IR
Adviser
ICR
Consilium
Mary-Jane Elliott
Chris Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
|
|
|
|
|
|
|
|
|
|
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our ExPERT™ platform,
which is based on our Flow Electroporation® technology, has been
designed to support the rapidly expanding cell therapy market and
can be utilized across the continuum of the high-growth cell
therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx™,
STx™, GTx™ and VLx™; a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by a
robust worldwide intellectual property
portfolio. By providing our partners with
the right technology platform, as well as scientific, technical,
and regulatory support, we aim to guide them on their journey to
transform human health. Learn more
at maxcyte.com and follow us
on X and LinkedIn.